UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2000
OR
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NUMBER 0-26483
VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)
DELAWARE
(State or other jurisdiction of incorporation or organization)
94-3236309
(I.R.S. Employer Identification Number)
1000 MARINA BLVD., SUITE 200
BRISBANE, CALIFORNIA 94005
(Address of Principal Administrative Offices) (Zip Code)
(650) 624-1000
(Registrants Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes /X/ No /_/
The issuer has one class of common stock with 13,706,136 shares outstanding as
of October 31, 2000.
<PAGE>
VAXGEN, INC.
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2000
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION PAGE
Item 1. Financial Statements:
Condensed Balance Sheets.........................................1
Condensed Statements of Operations...............................2
Condensed Statements of Cash Flows...............................3
Notes to Condensed Financial Statements..........................4
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations:
Overview.........................................................6
Results of Operations............................................8
Liquidity and Capital Resources..................................10
Item 3. Quantitative and Qualitative Disclosure about Market Risk.........12
PART II. OTHER INFORMATION
Item 2. Changes in Securities and Use of Proceeds.........................13
Item 5. Other Information ................................................13
Item 6. Exhibits and Reports on Form 8-K..................................14
Signature.........................................................15
<PAGE>
Item 1. Financial Statements
VAXGEN, INC.
(A Development Stage Enterprise)
CONDENSED BALANCE SHEETS
(Unaudited)
Item 1. FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
ASSETS
SEPTEMBER 30, DECEMBER 31,
2000 1999
--------------- ---------------
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $ 12,211,000 $ 16,063,000
Investment securities 42,994,000 54,471,000
Interest receivable 810,000 514,000
Prepaid expenses and other current assets 1,541,000 1,151,000
--------------- ---------------
TOTAL CURRENT ASSETS 57,556,000 72,199,000
Property and equipment, net 3,046,000 2,856,000
Other assets 224,000 170,000
--------------- ---------------
TOTAL ASSETS $ 60,826,000 $ 75,225,000
=============== ===============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Payable to Genentech $ 1,270,000 $ 817,000
Accounts payable 230,000 509,000
Accrued liabilities 2,913,000 2,629,000
Current portion of long-term obligations 31,000 31,000
--------------- ---------------
TOTAL CURRENT LIABILITIES 4,444,000 3,986,000
LONG-TERM OBLIGATIONS 64,000 89,000
STOCKHOLDERS' EQUITY:
Preferred stock, $0.01 par value, 20,000,000 shares
authorized; none issued or outstanding - -
Common stock, $0.01 par value, 20,000,000 shares
authorized; 13,611,259 and 13,511,565 shares issued
and outstanding at September 30, 2000 and
December 31, 1999, respectively 136,000 135,000
Additional paid-in capital 112,325,000 111,034,000
Deferred stock compensation (2,036,000) (2,225,000)
Accumulated other comprehensive income/(loss) -
unrealized gain/(loss) on investment securities 5,000 (125,000)
Deficit accumulated during the development stage (54,112,000) (37,669,000)
--------------- ---------------
TOTAL STOCKHOLDERS' EQUITY 56,318,000 71,150,000
--------------- ---------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 60,826,000 $ 75,225,000
=============== ===============
</TABLE>
See accompanying notes to condensed financial statements.
1
<PAGE>
VAXGEN, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30, PERIOD FROM
------------------------------ ---------------------------- NOVEMBER 27, 1995
(INCEPTION) THROUGH
2000 1999 2000 1999 SEPTEMBER 30, 2000
------------- ------------- ----------- ------------ -------------------
<S> <C> <C> <C> <C> <C>
Revenue:
Grant revenue $ 200,000 $ - $ 200,000 $ - $ 200,000
Operating expenses:
Research and development:
Genentech charges ..................... 1,600,000 424,000 2,260,000 819,000 8,406,000
Other ................................. 3,801,000 5,238,000 11,997,000 12,077,000 35,518,000
----------- ----------- ------------ ------------ ------------
Total research and development ........ 5,401,000 5,662,000 14,257,000 12,896,000 43,924,000
General and administrative expenses ... 2,018,000 1,145,000 5,383,000 5,948,000 17,404,000
----------- ----------- ------------ ------------ ------------
Loss from operations .................. (7,219,000) (6,807,000) (19,440,000) (18,844,000) (61,128,000)
Other income (expense) :
Investment income, net ................ 971,000 711,000 3,012,000 1,229,000 7,078,000
Interest expense ...................... (9,000) (5,000) (15,000) (6,000) (62,000)
----------- ----------- ------------ ------------ ------------
Total other income, net................ 962,000 706,000 2,997,000 1,223,000 7,016,000
----------- ----------- ------------ ------------ ------------
Net loss ..............................$( 6,257,000) $(6,101,000) $(16,443,000) $(17,621,000) $(54,112,000)
============ ============ ============ ============ ============
Basic and diluted loss per share ......$ (0.46) $ (0.55) $ (1.21) $ (2.00)
Weighted average shares used in
computing basic and diluted loss
per share 13,605,000 11,156,000 13,570,000 8,831,000
=========== =========== ============ ============
</TABLE>
See accompanying notes to condensed financial statements.
2
<PAGE>
VAXGEN, INC.
(A Development Stage Enterprise)
STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
PERIOD FROM
Nine Months Ended November 27, 1995
September 30, (inception) through
------------------------------------
2000 1999 September 30, 2000
---------------- ---------------- ------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
<S> <C> <C> <C>
NET LOSS $ (16,443,000) $ (17,621,000) $ (54,112,000)
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and amortization 565,000 323,000 1,153,000
Amortization of premiums and discounts on investment securities 341,000 186,000 (474,000)
Stock compensation expense 662,000 3,124,000 3,994,000
Changes in assets and liabilities:
Interest receivable (296,000) (200,000) (810,000)
Prepaid expenses and other current assets (390,000) (984,000) (1,541,000)
Other assets (55,000) 3,000 (113,000)
Payable to Genentech 453,000 598,000 1,270,000
Accounts payable and accrued liabilities 5,000 1,132,000 3,143,000
---------------- ---------------- ------------------
NET CASH USED IN OPERATING ACTIVITIES (15,158,000) (13,439,000) (47,490,000)
---------------- ---------------- ------------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investment securities (16,567,000) (48,148,000) (133,679,000)
Sale and maturities of investment securities 27,833,000 9,767,000 91,164,000
Purchase of property and equipment (754,000) (1,685,000) (4,052,000)
Long-term lease deposits - - (120,000)
---------------- ---------------- ------------------
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 10,512,000 (40,066,000) (46,687,000)
---------------- ---------------- ------------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments under capital lease obligations (25,000) (13,000) (43,000)
Stock issued to Genentech - - 1,025,000
Stock issued to other founders - - 20,000
Stock issued in private placements - 5,537,000 65,164,000
Stock issued in initial public offering - 46,345,000 46,345,000
Issuance costs of private placements - (264,000) (4,208,000)
Issuance costs of initial public offering - (4,328,000) (4,386,000)
Exercise of employee stock options 819,000 - 1,471,000
Loans from Genentech - - 1,000,000
---------------- ---------------- ------------------
NET CASH PROVIDED BY FINANCING ACTIVITIES 794,000 47,277,000 106,388,000
---------------- ---------------- ------------------
INCREASE (DECREASE) IN CASH AND EQUIVALENTS (3,852,000) (6,228,000) 12,211,000
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 16,063,000 6,818,000 -
---------------- ---------------- ------------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 12,211,000 $ 590,000 $ 12,211,000
================ ================ ==================
SUPPLEMENTAL SCHEDULE OF NON CASH FINANCING ACTIVITIES:
Equipment acquired through capital leases $ - $ 138,000 $ 138,000
Issuance of stock through conversion of Genentech note payable $ - $ - $ 1,000,000
</TABLE>
See accompanying notes to condensed financial statements.
3
<PAGE>
VAXGEN, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2000
(UNAUDITED)
1. BASIS OF PRESENTATION
The unaudited condensed financial statements of VaxGen, Inc. (the "Company")
included herein have been prepared by the Company pursuant to the rules and
regulations of the Securities and Exchange Commission. Certain information or
footnote disclosure normally included in financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to such rules and regulations. In the opinion of the management
of the Company, the accompanying unaudited condensed financial statements
contain all adjustments, consisting only of normal recurring adjustments,
necessary to present fairly the financial information included herein. While the
Company believes that the disclosures are adequate to make the information not
misleading, it is suggested that these financial statements should be read in
conjunction with the Company's audited financial statements contained in its
Annual Report on Form 10-K for the year ended December 31, 1999.
2. NON-CASH COMPENSATION
On April 1, 1999, the shareholders of the Company approved an increase in the
number of shares reserved for grant under the Company's 1996 Stock Option Plan
to 1,750,000 shares. This represents the measurement date for stock options
granted to employees earlier in 1999 and in 1998, which were granted subject to
stockholder approval of the plan amendment. As a result, the Company recorded
deferred compensation in the amount of $3,223,000, representing the excess of
fair market value of the common shares on April 1, 1999, $13.00 per share, over
the exercise price of the options on the date stockholder approval was obtained.
The Company has recorded charges to non-cash compensation expense of $563,000
for the portion of the vesting period lapsed for the nine months ended September
30, 2000. The balance of deferred compensation is being amortized to expense
over the remaining vesting period of the options.
4
<PAGE>
VAXGEN, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
3. LOSS PER SHARE
Excluded from the computation of basic and diluted loss per share, were stock
options and warrants outstanding for the purchase of 1,998,000 and 1,674,000
shares of common stock as of September 30, 2000 and September 30, 1999,
respectively, because the representative share increments would be antidilutive.
4. NEW ACCOUNTING PRONOUNCEMENTS
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133,
"Accounting for Derivative Instruments and Hedging Activities." SFAS No. 133 is
effective for fiscal years beginning after June 15, 2000. SFAS No. 133 requires
that all derivative instruments be recorded on the balance sheet at their fair
value. Changes in the fair value of derivatives are recorded each period in
current earnings or other comprehensive income, depending on whether a
derivative is designated as part of a hedge transaction and, if it is, the type
of hedge transaction. The Company does not expect that the adoption of SFAS No.
133 will have a material impact on its financial statements.
In March 2000, the Securities and Exchange Commission (SEC) issued Staff
Accounting Bulletin (SAB) No. 101B. SAB 101B delays the effective date of SAB
101, "Revenue Recognition in Financial Statements," to the fourth quarter for
fiscal years beginning after December 15,1999. SAB 101 provides guidance on
revenue recognition and the SEC staff's views on the application of accounting
principles to selected revenue recognition issues. The Company does not expect
that the adoption of SAB 101 will have a material impact on its financial
statements.
In March 2000, the Financial Accounting Standards Board issued Interpretation
No. 44 (FIN 44), "Accounting for Certain Transactions involving Stock
Compensation." FIN 44 clarifies the application of Accounting Principles Board
Opinion No. 25 (APB 25) and is effective July 1, 2000. FIN 44 clarifies the
definition of "employee" for purposes of applying APB 25, the criteria for
determining whether a plan qualifies as a non-compensatory plan, the accounting
consequence of various modifications to the terms of a previously fixed stock
option or award, and the accounting for an exchange of stock compensation awards
in a business combination. The impact of the interpretation on the Company's
financial position and results of operations was not material.
5
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
This discussion and analysis should be read in conjunction with our condensed
financial statements and related notes thereto appearing in Item 1 of this
report. In addition to historical information, this report contains
"forward-looking statements" that are within the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, and that are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those projected. The words "believe", "expect", "intend",
"anticipate", and similar expressions are used to identify forward-looking
statements, but their absence does not mean that such statement is not
forward-looking. Many factors could affect the Company's actual results,
including those factors described under "Factors Affecting Future Results" and
"Business" contained in the Company's Annual Report on Form 10-K for the year
ended December 31, 1999. These risk factors, among others, could cause results
to differ materially from those presently anticipated by the Company. Readers
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this report. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
after the date of this report or to reflect the occurrence of anticipated
events.
OVERVIEW
In November 1995, VaxGen was formed to continue development of AIDSVAX(R). At
that time, Genentech, Inc. ("Genentech") licensed to us the technology necessary
for completing development and commercialization of AIDSVAX(R). Currently,
Genentech owns approximately 11% of VaxGen common stock.
Since our formation, we have focused on developing and testing AIDSVAX(R). We
have developed formulations of AIDSVAX(R), which focus on the predominant HIV
subtype in North America, Europe, the Caribbean, and Australia (subtype B) and
the predominant HIV subtype in Southeast Asia and East Asia (subtype E). We have
commenced two Phase III clinical trials, one in North America and Europe and one
in Thailand to determine the efficacy of AIDSVAX(R). In October 1999, we
completed the initial inoculation and enrollment of over 5,400 trial volunteers
for the North American/European Phase III clinical trial, which is being
conducted in 61 clinical centers. In August 2000, we completed the initial
inoculation and enrollment of over 2,500 volunteers for the Thai Phase III
clinical trial, which is being conducted in 17 clinical centers in Bangkok.
To date, we have generated $200,000 in revenue from a preparedness grant from
the National Institutes of Health for research and development of HIV vaccines.
We anticipate only modest revenues from other governmental agencies or other
grants or from collaborations with other entities over the next three to four
years. We have incurred losses since inception as a result of research and
development and general and
6
<PAGE>
administrative expenses in support of our operations. As of September 30, 2000,
we had a deficit accumulated during the development stage of $54,112,000. We
anticipate incurring substantial losses over at least the next three to four
years as we complete our clinical trials, apply for regulatory approvals,
continue development of our technology and expand our operations.
An interim efficacy analysis of the North American/European Phase III clinical
trial is scheduled for the fourth quarter of 2001. If the analysis yields
sufficient statistical evidence to show that AIDSVAX(R) is effective, the
Company, based upon the independent Data and Safety Monitoring Board's
recommendation, will halt the trial and apply for regulatory approval. If the
interim analysis is inconclusive, the Company will proceed as planned and
complete the trial at the end of 2002. We anticipate that all the phases
associated in obtaining regulatory approval will take approximately 24 months to
complete.
In the future, we may have additional non-cash compensation expense due to a
success bonus provision contained in employment agreements we have with three of
our executive officers. Our employment agreements with these officers provide
for issuance of an aggregate of 325,757 shares of common stock if:
o The public market valuation of a share of the Company's common
stock, as computed on a 30-day trailing average based on the average
daily closing price of the Company's common stock over such period as
reported by the Nasdaq Stock Market(R), is equal to or greater than
$28.00 per share; or
o There is an acquisition of the Company through tender offer or
otherwise in which all shareholders have the opportunity to
participate and realize a value equal to or greater than $28.00 per
share.
If the shares are issued, we will record non-cash compensation expense equal to
the aggregate value of shares on the date the $28.00 per share condition is met.
For example, if the per share value of the stock upon issuance is $28.00, the
charge to expense would be approximately $9,100,000 or an additional loss of
$0.65 per share, based upon shares outstanding at September 30, 2000 after
giving effect to the issuance of these shares. The aggregate issuance of the
shares would have a dilutive effect of approximately 2.3%, based upon shares
outstanding at September 30, 2000 after giving effect to the issuance of these
shares.
<PAGE>
We have a license and supply agreement with Genentech, whereby Genentech
supplies clinical material for all of our clinical sites. We incurred expense of
$1,300,000 for clinical material in the third quarter of 2000. We anticipate
that we will incur another $1,200,000 for clinical material over the next two
years.
7
<PAGE>
RESULTS OF OPERATIONS
NINE MONTHS ENDED SEPTEMBER 30, 2000 COMPARED TO THE NINE MONTHS ENDED SEPTEMBER
30, 1999
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses increased 11% from $12,896,000 for the nine
months ended September 30, 1999 to $14,257,000 for the nine months ended
September 30, 2000. The increase is related to the on-going North
American/European and Thai clinical trials along with development of additional
AIDSVAX(R) vaccines (see further discussion in "Liquidity and Capital
Resources"). These expenses included costs for additional personnel, non-cash
compensation expense related to vesting of stock options, maintaining our new
research laboratory facility and increases in fees paid to third parties
associated with conducting the clinical trials.
GENERAL AND ADMINISTRATIVE EXPENSES
General and administrative expenses decreased 9% from $5,948,000 for the nine
months ended September 30, 1999 to $5,383,000 for the nine months ended
September 30, 2000. The decrease was due primarily to non-cash compensation
expense recorded in the second quarter of 1999 related to the issuance of
warrants and modification of the terms of options in connection with resolving
two employment matters offset by increased expenses incurred in 2000 related to
additional personnel hired to support our growing infrastructure, equipment
expense related to larger office facilities and certain administrative expenses
associated with being a public company.
OTHER INCOME, NET
Other income, net, consisting primarily of investment income, increased by 145%
from $1,223,000 for the nine months ended September 30, 1999 to $2,997,000 for
the nine months ended September 30, 2000. This was primarily attributed to
higher average balances of cash, cash equivalents and investment securities as a
result of funds received from the initial public offering completed during the
third quarter of 1999 and a private placement completed in the fourth quarter of
1999.
NET LOSS
Net loss for the nine months ended September 30, 2000, was $16,443,000 compared
to a loss of $17,621,000 for the comparable period in 1999. The decrease in net
loss was due to non-cash compensation expense in 1999 and an increase in
investment income offset by an increase in expenses in 2000 as noted above.
8
<PAGE>
THREE MONTHS ENDED SEPTEMBER 30, 2000 COMPARED TO THE THREE MONTHS ENDED
SEPTEMBER 30, 1999
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses decreased 5% from $5,662,000 for the three
months ended September 30, 1999 to $5,401,000 for the three months ended
September 30, 2000. The decrease is related to decreases in fees paid to third
parties associated with conducting the clinical trials offset by expenses
related to the on-going North American/European and Thai clinical trials along
with development of additional AIDSVAX(R) vaccines (see further discussion in
"Liquidity and Capital Resources"). These expenses included costs for additional
personnel, non-cash compensation expense related to vesting of stock options,
maintaining our new research laboratory facility.
GENERAL AND ADMINISTRATIVE EXPENSES
General and administrative expenses increased 76% from $1,145,000 for the three
months ended September 30, 1999 to $2,018,000 for the three months ended
September 30, 2000. The increase was due primarily to additional personnel hired
to support our growing infrastructure, non-cash compensation expense related to
vesting of stock options, equipment expense related to larger office facilities
and certain administrative expenses associated with being a public company.
OTHER INCOME, NET
Other income, net, consisting primarily of investment income, increased by 36%
from $706,000 for the three months ended September 30, 1999 to $962,000 for the
three months ended September 30, 2000. This was primarily attributed to higher
average balances of cash, cash equivalents and investment securities as a result
of funds received from a private placement completed in the fourth quarter of
1999.
NET LOSS
Net loss for the three months ended September 30, 2000, was $6,257,000 compared
to a loss of $6,101,000 for the comparable period in 1999. The decrease was due
to non-cash compensation expense in 1999 and an increase in investment income
offset by an increase in expenses in 2000 as noted above.
9
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES
Cash, cash equivalents and investment securities were $55,205,000 at September
30, 2000. We have financed our operations since inception through capital
provided by Genentech and sales of our common stock. Genentech has no obligation
to provide future funding to the Company.
We completed our initial public offering ("IPO") in July 1999, in which we
issued and sold 3,565,000 shares of common stock for aggregate proceeds to us in
the amount of $46,345,000. Of the aggregate proceeds received in the IPO,
approximately $4,400,000 was used to pay costs and expenses related to the IPO,
resulting in net proceeds of approximately $42,000,000. In early 1999, we
received net proceeds of $5,273,000 from private placement financing activities,
all of which were completed prior to the IPO.
In December 1999, we completed a private placement of common stock with Vulcan
Ventures, Inc., the investment organization of Paul G. Allen. The funds from the
private placement support our on-going operations along with our current
clinical trials. This private placement has also enabled us to commence
development of a formulation of AIDSVAX(R), which focuses on the predominant HIV
type found in Africa, China, India and South America (subtype C). Currently, we
have developed formulations of AIDSVAX(R), which focus on the predominant HIV
type in North America, Europe, the Caribbean and Australia (subtype B) and the
predominant HIV subtype in Southeast Asia and East Asia (subtype E). The private
placement consisted of approximately 2,174,000 shares of common stock, which
resulted in proceeds, net of expenses, to us of approximately $24,000,000.
Since our inception, investing activities, other than purchases and sales of
investment securities, have consisted entirely of equipment acquisitions and
leasehold improvements. From inception through September 30, 2000, our gross
investment in equipment and leasehold improvements was $4,052,000. The increase
in equipment and leasehold improvements has been primarily due to the
development of our research and development laboratory and the establishment of
larger office facilities. Net cash used in operating activities for the nine
months ended September 30, 2000 was $15,158,000 representing expenditures for
research and development costs and general and administrative expenses.
In October 1999, we entered into a collaboration with the federal Centers for
Disease Control and Prevention ("CDC") to support research at six of the 56
clinics in the United States currently conducting Phase III clinical trials of
our AIDSVAX(R) vaccine. The CDC selected the six sites in the fourth quarter of
1999. Contractual arrangements between the CDC and the clinics were completed in
the second quarter of 2000. The participating sites will continue to implement
our Phase III protocol, as well as conduct epidemiological, social and
behavioral research, which will be shared by the Company and the CDC. The sites
will be compensated directly by the CDC for the clinical costs, which would have
been incurred by the Company, and for conducting the additional research. The
CDC has agreed to contribute approximately $8,000,000 to the participating sites
over a four=year period.
10
<PAGE>
The National Institute of Allergy and Infectious Diseases ("NIAID") is
negotiating a collaboration with us to obtain and store clinical specimens from
our North American/European Phase III clinical trial. The proposal provides that
NIAID may fund approximately $4,600,000 for this program. The majority of the
funding would go to third parties for their participation in the program.
Consummation of the collaboration remains subject to final approval of the
collaborative agreement by both parties.
An interim efficacy analysis of the North American/European Phase III clinical
trial is scheduled for the fourth quarter of 2001. If the analysis yields
sufficient statistical evidence to show that AIDSVAX(R) is effective, the
Company, based upon the independent Data and Safety Monitoring Board's
recommendation, will halt the trial and apply for regulatory approval. If the
interim analysis is inconclusive, the Company will proceed as planned and
complete the trial at the end of 2002. We anticipate that all the phases
associated in obtaining regulatory approval will take approximately 24 months to
complete.
We believe that our existing cash and cash equivalents and investment
securities, together with investment income along with funds from other
potential collaborative arrangements, will enable us to meet our forecasted
expenditures through the anticipated completion of our North American/European
Phase III clinical trial. However, we may need to raise additional funds to
complete the Thai Phase III clinical trial and will need to raise additional
funds to support the necessary manufacturing and development programs required
in obtaining regulatory approval.
We will also need to raise additional capital if the Phase III clinical trials
are further delayed or more costly than currently anticipated, or to continue
operations if the Phase III clinical trials are not successful, or if
commercialization is delayed for any other reason. Our future capital
requirements are also dependent on several other factors, including:
o the progress of other internal research and development projects;
o the need for leasehold improvements to facilities and the purchase of
additional capital equipment;
o the ability to attract and negotiate business development opportunities;
and
o the timing of revenue, if any, from AIDSVAX(R)
We cannot assure you that we will be able to raise funds when needed, or that
such funds will be available on satisfactory terms. We expect that our ability
to raise additional capital will be importantly effected by whether AIDSVAX(R)
achieves clinical success at either the interim or final analysis. However, if
clinical success is achieved at either point of analysis, we do not expect
difficulty in raising additional capital.
Our exposure to market rate changes is related primarily to our debt securities
included in our investment portfolio. We do not have any derivative financial
instruments. By policy, we invest in debt instruments of the U. S. Government
and high-quality corporate issuers, limit the amount of credit exposure to any
one issuer, limit duration by restricting the term, and hold investments to
maturity except under rare circumstances. Investments in both fixed rate and
floating rate instruments carry a degree of interest rate risk. Fixed rate
securities may have their fair market value adversely impacted due to a rise in
interest rates, while floating rate securities may produce less income than
expected if interest rates fall. Due in part to these factors, our future
investment income may decrease due to changes in interest rates or due to losses
we may suffer when securities decline in market value. At September 30, 2000, we
held government debt instruments in the principal amount of $16,960,000. If
market interest rates were to increase immediately and uniformly by 10% from
levels at September 30, 2000, the fair value of our portfolio would decline by
an immaterial amount. Our exposure to losses as a result of interest rate
changes is managed through investing primarily in securities that mature in a
period of one year or less.
We have exposure to foreign exchange rate risk primarily related to our
conducting clinical trials in Thailand. Thailand is currently considered an
emerging economy. A material increase in the value of Thailand's currency
against the U.S. Dollar could cause
11
<PAGE>
an increase in our expenses. The majority of our contracts associated with
conducting clinical trials in Thailand are priced in Baht. At the time these
contracts were written, the Thailand exchange rate was 37.5 Baht per one U. S.
Dollar. As of September 30, 2000, we have incurred $1,000 in foreign exchange
losses.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Information relating to quantitative and qualitative disclosure about market
risk is set forth under the caption "Liquidity and Capital Resources" in Part I,
Item 2, Management's Discussion and Analysis of Financial Condition and Results
of Operations.
12
<PAGE>
PART II - OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
The Company's Registration Statement under the Securities Act of 1933 (File No.
333-78065) became effective June 29, 1999. Offering proceeds, net of aggregate
expenses of approximately $4,400,000, were approximately $42,000,000. All of the
expenses related to the offering were direct or indirect payments to others and
not payments to our directors or officers (or their associates) or to our
affiliates or 10% shareholders. As of September 30, 2000, the Company has
utilized approximately $11,000,000 of net proceeds of the offering for operating
activities, capital expenditures, as well as for other general corporate
purposes. The Company has invested the remainder of the net proceeds from the
offering in investments such as high-quality corporate issues and government
obligations.
ITEM 5. OTHER INFORMATION
On November 9, 2000, the Company issued a press release relating to the
resignation of one of its directors. The Company announced that Roberta R. Katz
resigned from the Company's Board of Directors due to personal reasons. Ms.
Katz, whose resignation was effective November 2, 2000, had been a member of the
Company's Board of Directors since September 1999.
13
<PAGE>
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits required by Item 601 and Regulation S-K:
27.1 Financial Data Schedule, which is submitted electronically to the
Securities and Exchange Commission for information purposes only and
is not deemed filed.
(b) Reports on Form 8-K:
None.
14
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
VaxGen, Inc.
(Registrant)
Dated: November 13, 2000 By: /S/ CARTER A. LEE
----------------------
Carter A. Lee
Senior Vice President
Finance & Administration
(Principal Financial Officer)
15
<PAGE>
